ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create highly effective and safe therapeutics. The company's AlphaDirect™ technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead program AB001 currently in first in human trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/07/23 | $90,000,000 | Series A |
F-Prime Capital Partners Omega Funds Third Rock Ventures  | undisclosed |
| 07/29/25 | $132,000,000 | Series B |
Alexandria Venture Investments B Capital F-Prime Capital Partners Omega Funds Qatar Investment Authority Sofinnova Investments Third Rock Ventures | undisclosed |
